Enhancement of ischemic flap survival by prefabrication with transfer of exogenous PDGF gene

Paul Y. Liu, Xiao Tian Wang, Evangelos V Badiavas, Kimberley Rieger-Christ, Jin Bo Tang, Ian Summerhayes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Treatment of skin flaps by means of gene therapy has been introduced recently as a novel approach to enhance viability of ischemic skin flaps. Transfer of the platelet-derived growth factor (PDGF) to enhance survival of the ischemic skin flap has not been explored. In this study, the authors investigated the effect of the transfer of the PDGF cDNA on survival and vascularity of the ischemic random flap in a rat model, and compared the effects of PDGF gene therapy to those of vascular endothelial growth factor (VEGF) gene therapy. A total of 45 adult Sprague-Dawley rats were randomly divided into four groups. The PDGF gene therapy group (n = 10) received the plasmid containing the PDGF cDNA with liposome injected to the dermis of the flap. A saline control group (n = 10) received physiologic saline only, and the vector control group (n = 10) received liposome plus vector without the PDGF gene segment. In the fourth group (n = 15), the VEGF gene was transferred to the flap. Seven days later, a dorsal random flap including the injection area was raised. One rat each from the saline and vector control groups died during the study period and were excluded. The viability of the flap and vascularity within the flaps were assessed 7 days after flap elevation. The PDGF plasmid-treated flaps had significantly greater survival area (60.8 ± 7.8 percent) compared with the flaps treated with saline (52.3 ± 5.0 percent) and those treated with liposome and vector (50.7 ± 5.9 percent). PDGF gene therapy had effects on survival of the flap similar to VEGF gene therapy (57.6 ± 5.2 percent, after transfer of VEGF cDNA). Neovascularization with the flap tissues was confirmed by immunohistochemical staining of von Willebrand factor, a marker specific for angiogenesis. The number of newly-formed blood vessels in the transgenic flaps was significantly greater than that of the vessels in the flaps receiving the saline. The findings of this study indicate that transfer of the PDGF cDNA effectively enhances neovascularization of the ischemic skin flap and increases the viability of the flap, and transfer of the PDGF gene is as efficient as transfer of the VEGF gene in improving viability of the skin flap. This study suggests that PDGF gene therapy may be a novel strategy for the treatment of ischemic skin flaps.

Original languageEnglish
Pages (from-to)273-279
Number of pages7
JournalJournal of Reconstructive Microsurgery
Volume21
Issue number4
DOIs
StatePublished - May 1 2005
Externally publishedYes

Fingerprint

Platelet-Derived Growth Factor
Genetic Therapy
Genes
Vascular Endothelial Growth Factor A
Skin
Complementary DNA
Liposomes
Control Groups
Plasmids
von Willebrand Factor
Dermis
Blood Vessels
Sprague Dawley Rats
Staining and Labeling

Keywords

  • Gene therapy
  • Immunohistochemistry
  • Ischemia
  • Neovascularization
  • Skin flap

ASJC Scopus subject areas

  • Surgery

Cite this

Enhancement of ischemic flap survival by prefabrication with transfer of exogenous PDGF gene. / Liu, Paul Y.; Wang, Xiao Tian; Badiavas, Evangelos V; Rieger-Christ, Kimberley; Tang, Jin Bo; Summerhayes, Ian.

In: Journal of Reconstructive Microsurgery, Vol. 21, No. 4, 01.05.2005, p. 273-279.

Research output: Contribution to journalArticle

Liu, Paul Y. ; Wang, Xiao Tian ; Badiavas, Evangelos V ; Rieger-Christ, Kimberley ; Tang, Jin Bo ; Summerhayes, Ian. / Enhancement of ischemic flap survival by prefabrication with transfer of exogenous PDGF gene. In: Journal of Reconstructive Microsurgery. 2005 ; Vol. 21, No. 4. pp. 273-279.
@article{af5826368f3d4e3cb84990cc3e45dfa9,
title = "Enhancement of ischemic flap survival by prefabrication with transfer of exogenous PDGF gene",
abstract = "Treatment of skin flaps by means of gene therapy has been introduced recently as a novel approach to enhance viability of ischemic skin flaps. Transfer of the platelet-derived growth factor (PDGF) to enhance survival of the ischemic skin flap has not been explored. In this study, the authors investigated the effect of the transfer of the PDGF cDNA on survival and vascularity of the ischemic random flap in a rat model, and compared the effects of PDGF gene therapy to those of vascular endothelial growth factor (VEGF) gene therapy. A total of 45 adult Sprague-Dawley rats were randomly divided into four groups. The PDGF gene therapy group (n = 10) received the plasmid containing the PDGF cDNA with liposome injected to the dermis of the flap. A saline control group (n = 10) received physiologic saline only, and the vector control group (n = 10) received liposome plus vector without the PDGF gene segment. In the fourth group (n = 15), the VEGF gene was transferred to the flap. Seven days later, a dorsal random flap including the injection area was raised. One rat each from the saline and vector control groups died during the study period and were excluded. The viability of the flap and vascularity within the flaps were assessed 7 days after flap elevation. The PDGF plasmid-treated flaps had significantly greater survival area (60.8 ± 7.8 percent) compared with the flaps treated with saline (52.3 ± 5.0 percent) and those treated with liposome and vector (50.7 ± 5.9 percent). PDGF gene therapy had effects on survival of the flap similar to VEGF gene therapy (57.6 ± 5.2 percent, after transfer of VEGF cDNA). Neovascularization with the flap tissues was confirmed by immunohistochemical staining of von Willebrand factor, a marker specific for angiogenesis. The number of newly-formed blood vessels in the transgenic flaps was significantly greater than that of the vessels in the flaps receiving the saline. The findings of this study indicate that transfer of the PDGF cDNA effectively enhances neovascularization of the ischemic skin flap and increases the viability of the flap, and transfer of the PDGF gene is as efficient as transfer of the VEGF gene in improving viability of the skin flap. This study suggests that PDGF gene therapy may be a novel strategy for the treatment of ischemic skin flaps.",
keywords = "Gene therapy, Immunohistochemistry, Ischemia, Neovascularization, Skin flap",
author = "Liu, {Paul Y.} and Wang, {Xiao Tian} and Badiavas, {Evangelos V} and Kimberley Rieger-Christ and Tang, {Jin Bo} and Ian Summerhayes",
year = "2005",
month = "5",
day = "1",
doi = "10.1055/s-2005-871755",
language = "English",
volume = "21",
pages = "273--279",
journal = "Journal of Reconstructive Microsurgery",
issn = "0743-684X",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Enhancement of ischemic flap survival by prefabrication with transfer of exogenous PDGF gene

AU - Liu, Paul Y.

AU - Wang, Xiao Tian

AU - Badiavas, Evangelos V

AU - Rieger-Christ, Kimberley

AU - Tang, Jin Bo

AU - Summerhayes, Ian

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Treatment of skin flaps by means of gene therapy has been introduced recently as a novel approach to enhance viability of ischemic skin flaps. Transfer of the platelet-derived growth factor (PDGF) to enhance survival of the ischemic skin flap has not been explored. In this study, the authors investigated the effect of the transfer of the PDGF cDNA on survival and vascularity of the ischemic random flap in a rat model, and compared the effects of PDGF gene therapy to those of vascular endothelial growth factor (VEGF) gene therapy. A total of 45 adult Sprague-Dawley rats were randomly divided into four groups. The PDGF gene therapy group (n = 10) received the plasmid containing the PDGF cDNA with liposome injected to the dermis of the flap. A saline control group (n = 10) received physiologic saline only, and the vector control group (n = 10) received liposome plus vector without the PDGF gene segment. In the fourth group (n = 15), the VEGF gene was transferred to the flap. Seven days later, a dorsal random flap including the injection area was raised. One rat each from the saline and vector control groups died during the study period and were excluded. The viability of the flap and vascularity within the flaps were assessed 7 days after flap elevation. The PDGF plasmid-treated flaps had significantly greater survival area (60.8 ± 7.8 percent) compared with the flaps treated with saline (52.3 ± 5.0 percent) and those treated with liposome and vector (50.7 ± 5.9 percent). PDGF gene therapy had effects on survival of the flap similar to VEGF gene therapy (57.6 ± 5.2 percent, after transfer of VEGF cDNA). Neovascularization with the flap tissues was confirmed by immunohistochemical staining of von Willebrand factor, a marker specific for angiogenesis. The number of newly-formed blood vessels in the transgenic flaps was significantly greater than that of the vessels in the flaps receiving the saline. The findings of this study indicate that transfer of the PDGF cDNA effectively enhances neovascularization of the ischemic skin flap and increases the viability of the flap, and transfer of the PDGF gene is as efficient as transfer of the VEGF gene in improving viability of the skin flap. This study suggests that PDGF gene therapy may be a novel strategy for the treatment of ischemic skin flaps.

AB - Treatment of skin flaps by means of gene therapy has been introduced recently as a novel approach to enhance viability of ischemic skin flaps. Transfer of the platelet-derived growth factor (PDGF) to enhance survival of the ischemic skin flap has not been explored. In this study, the authors investigated the effect of the transfer of the PDGF cDNA on survival and vascularity of the ischemic random flap in a rat model, and compared the effects of PDGF gene therapy to those of vascular endothelial growth factor (VEGF) gene therapy. A total of 45 adult Sprague-Dawley rats were randomly divided into four groups. The PDGF gene therapy group (n = 10) received the plasmid containing the PDGF cDNA with liposome injected to the dermis of the flap. A saline control group (n = 10) received physiologic saline only, and the vector control group (n = 10) received liposome plus vector without the PDGF gene segment. In the fourth group (n = 15), the VEGF gene was transferred to the flap. Seven days later, a dorsal random flap including the injection area was raised. One rat each from the saline and vector control groups died during the study period and were excluded. The viability of the flap and vascularity within the flaps were assessed 7 days after flap elevation. The PDGF plasmid-treated flaps had significantly greater survival area (60.8 ± 7.8 percent) compared with the flaps treated with saline (52.3 ± 5.0 percent) and those treated with liposome and vector (50.7 ± 5.9 percent). PDGF gene therapy had effects on survival of the flap similar to VEGF gene therapy (57.6 ± 5.2 percent, after transfer of VEGF cDNA). Neovascularization with the flap tissues was confirmed by immunohistochemical staining of von Willebrand factor, a marker specific for angiogenesis. The number of newly-formed blood vessels in the transgenic flaps was significantly greater than that of the vessels in the flaps receiving the saline. The findings of this study indicate that transfer of the PDGF cDNA effectively enhances neovascularization of the ischemic skin flap and increases the viability of the flap, and transfer of the PDGF gene is as efficient as transfer of the VEGF gene in improving viability of the skin flap. This study suggests that PDGF gene therapy may be a novel strategy for the treatment of ischemic skin flaps.

KW - Gene therapy

KW - Immunohistochemistry

KW - Ischemia

KW - Neovascularization

KW - Skin flap

UR - http://www.scopus.com/inward/record.url?scp=19344368832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19344368832&partnerID=8YFLogxK

U2 - 10.1055/s-2005-871755

DO - 10.1055/s-2005-871755

M3 - Article

C2 - 15971146

AN - SCOPUS:19344368832

VL - 21

SP - 273

EP - 279

JO - Journal of Reconstructive Microsurgery

JF - Journal of Reconstructive Microsurgery

SN - 0743-684X

IS - 4

ER -